Sanofi to acquire rights to develop, commercialize aficamten

Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. | As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China.
Sanofi To Buy Rights To Develop Cytokinetics' Aficamten In Greater China From Corxel
Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major
Cytokinetics stock rises on Sanofi's rights acquisition
Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (EPA:SASY) (NASDAQ:SNY) will acquire exclusive rights to develop and commercialize aficamten in Greater China, a move that underscores the drug's potential in treating hypertrophic cardiomyopathy (HCM).
Sanofi to buy China rights to Cytokinetics lead asset
Cytokinetics (NASDAQ:CYTK) announced Friday that Sanofi (NASDAQ:SNY) would buy exclusive rights to its lead candidate, aficamten, in Greater China from its partner, Corxel Pharmaceuticals. The company didn’t disclose the financial terms of the agreement between but said it remains on track to receive up to $150M in milestone payments and low-to-high teens on aficamten sales from the French drugmaker.
Sanofi to acquire rights to develop, commercialize aficamten from Corxel
Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel
Why Cytokinetics Stock Was a Nearly 5% Winner Today
California-based biotech Cytokinetcs ( CYTK 4.56%) finished the trading week in style, as its stock price outperformed many ...
Hosted on MSN17d
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has ...
Cytokinetics' application for aficamten accepted by FDA
Cytokinetics (NASDAQ:CYTK) said the FDA has accepted its New Drug Application for aficamten for the treatment of obstructive ...
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $83.93 Consensus Price Target from Analysts
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has been given a consensus rating of “Moderate Buy” by the sixteen analysts that are currently covering the stock, Marketbeat reports. Four ...
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nasdaq19d
Cytokinetics opens enrollment for COMET-HF Phase 3 trial
Cytokinetics (CYTK) announced that COMET-HF, a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction ...
Business Insider4d
Cytokinetics price target raised to $82 from $80 at RBC Capital
RBC Capital raised the firm’s price target on Cytokinetics (CYTK) to $82 from $80 and keeps an Outperform rating on the shares. Given the potential advantages that the company’s aficamten may have ...